Pyrrolidine dithiocarbamate inhibits herpes simplex virus 1 and 2 replication, and its activity may be mediated through dysregulation of the ubiquitin-proteasome system

Journal of Virology

Volumn 87, Issue 15, 2013, Pages 8675-8686

  Qiu, Min ^a   Chen, Yu ^a   Cheng, Lin ^a   Chu, Ying ^a   Song, Hong Yong ^a   Wu, Zhi Wei ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

26S PROTEASOME; CELL PROTEIN; I KAPPA B ALPHA; IMMEDIATE EARLY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; UBIQUITIN; UNCLASSIFIED DRUG; ZINC ION;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IMMEDIATE EARLY GENE; MEMBRANE PROTEIN GD GENE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROGENY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION; VIRUS GENE; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CATIONS, DIVALENT; CELL LINE; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLIDINES; THIOCARBAMATES; UBIQUITIN; VIRUS REPLICATION; ZINC;

EID: 84880600373     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00869-13     Document Type: Article

References (80)

1. Ahmad N, Ray CG, Drew WL. 2011. Chapter 14. Herpesviruses, p 247-270. In Ryan KJ, Ray CG (ed), Sherris medical microbiology, 5th ed.McGraw Hill Medical, New York, NY.
2. Kapiga SH, Sam NE, Bang H, Ni Q, Ao TTH, Kiwelu I, Chiduo S, Ndibe U, Seage G, Coplan P. 2007. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J. Infect. Dis. 195:1260-1269.
3. Lama JR, Lucchetti A, Suarez L, Laguna-Torres VA, Guanira JV, Pun M, Montano SM, Celum CL, Carr JK, Sanchez J. 2006. Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru. J.Infect. Dis. 194:1459-1466.
4. Itzhaki RF, Wozniak MA. 2008. Herpes simplex virus type 1 in Alzheimer's disease: the enemy within. J. Alzheimers Dis. 13:393-405.
5. Holmes C, Cotterell D. 2009. Role of infection in the pathogenesis of Alzheimers disease: implications for treatment. CNS Drugs 23:993-1002.
6. Lee YW, Hennig B, Toborek M. 2003. Redox-regulated mechanisms of IL-4-induced MCP-1 expression in human vascular endothelial cells. Am.J. Physiol. Heart Circ. Physiol. 284:H185-H192.
7. Si X, McManus BM, Zhang J, Yuan J, Cheung C, Esfandiarei M, Suarez A, Morgan A, Luo H. 2005. Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J. Virol. 79:8014-8023.
8. Gaudernak E, Seipelt J, Triendl A, Grassauer A, Kuechler E. 2002.Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses. J.Virol. 76:6004-6015.
9. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, Kikugawa K. 2003. Evidence that reactive oxygen species do not mediate NFκB activation. EMBO J. 22:3356-3366.
10. Schreck R, Meier B, Männel DN, Dräge W, Baeuerle PA. 1992. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 175:1181-1194.
11. Ziegler-Heitbrock H, Sternsdorf T, Liese J, Belohradsky B, Weber C,Wedel A, Schreck R, Bauerle P, Strobel M. 1993. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J. Immunol. 151:6986-6993.
12. 2+ complex in the cultured rat cortical astrocytes. Glia 31:249-261.
13. 2+. Am. J. Physiol. Cell Physiol. 278:C1116-C1125.
14. Chung KC, Park JH, Kim CH, Lee HW, Sato N, Uchiyama Y, Ahn YS.2000. Novel biphasic effect of pyrrolidine dithiocarbamate on neuronal cell viability is mediated by the differential regulation of intracellular zinc and copper ion levels, NFΚ b, and MAP kinases. J. Neurosci. Res. 59:117-125.
15. Kim I, Kim CH, Kim JH, Lee J, Choi JJ, Chen ZA, Lee MG, Chung KC, Hsu CY, Ahn YS. 2004. Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis. Exp. Cell Res. 298:229-238.
16. Peters J, Franke W, Kleinschmidt J. 1994. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J. Biol. Chem. 269:7709-7718.
17. Goldberg A. 2007. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans.35:12-17.
18. Pickart CM. 2004. Back to the future with ubiquitin. Cell 116:181-190.
19. Banks L, Pim D, Thomas M. 2003. Viruses and the 26S proteasome:hacking into destruction. Trends Biochem. Sci. 28:452-459.
20. Boutell C, Sadis S, Everett RD. 2002. Herpes simplex virus type 1 immediate-early protein ICP0 and its isolated RING finger domain act as ubiquitin E3 ligases in vitro. J. Virol. 76:841-850.
21. Van Sant C, Hagglund R, Lopez P, Roizman B. 2001. The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes,binds and activates the cdc34 E2 ubiquitin-conjugating enzyme,and possesses in vitro E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci.U. S. A. 98:8815-8820.
22. Boutell C, Orr A, Everett RD. 2003. PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J. Virol. 77:8686-8694.
23. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, Orr A. 2006.PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 80:7995-8005.
24. Chelbi-Alix MK. 1999. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18:935-941.
25. Lomonte P, Morency E. 2007. Centromeric protein CENP-B proteasomal degradation induced by the viral protein ICP0. FEBS Lett. 581:658-662.
26. Everett RD, Earnshaw WC, Findlay J, Lomonte P. 1999. Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. EMBO J. 18: 1526-1538.
27. Lomonte P, Sullivan KF, Everett RD. 2001. Degradation of nucleosomeassociated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. J. Biol. Chem. 276:5829-5835.
28. Fukuyo Y, Horikoshi N, Ishov AM, Silverstein SJ, Nakajima T. 2011.The herpes simplex virus immediate-early ubiquitin ligase ICP0 induces degradation of the ICP0 repressor protein E2FBP1. J. Virol. 85:3356-3366.
29. Delboy MG, Roller DG, Nicola AV. 2008. Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step. J. Virol.82:3381-3390.
30. Delboy MG, Nicola AV. 2011. A pre-immediate-early role for tegument ICP0 in the proteasome-dependent entry of herpes simplex virus. J. Virol.85:5910-5918.
31. Uchide N, Ohyama K, Bessho T, Yuan B, Yamakawa T. 2002. Effect of antioxidants on apoptosis induced by influenza virus infection: inhibition of viral gene replication and transcription with pyrrolidine dithiocarbamate.Antiviral Res. 56:207-217.
32. Krenn B, Holzer B, Gaudernak E, Triendl A, Van Kuppeveld F, Seipelt J. 2005. Inhibition of polyprotein processing and RNA replication of human rhinovirus by pyrrolidine dithiocarbamate involves metal ions. J. Virol. 79:13892-13899.
33. Lanke K, Krenn B, Melchers W, Seipelt J, van Kuppeveld F. 2007. PDTC inhibits picornavirus polyprotein processing and RNA replication by transporting zinc ions into cells. J. Gen. Virol. 88:1206-1217.
34. Furuta S, Ortiz F, Sun XZ, Wu HH, Mason A, Momand J. 2002. Copper uptake is required for pyrrolidine dithiocarbamate-mediated oxidation and protein level increase of p53 in cells. Biochem. J. 365:639-648.
35. Kim CH, Kim JH, Hsu CY, Ahn YS. 1999. Zinc is required in pyrrolidine dithiocarbamate inhibition of NFΚB activation. FEBS Lett. 449:28-32.
36. Everett R. 1984. Trans activation of transcription by herpes virus products: requirement for two HSV-1 immediate-early polypeptides for maximum activity. EMBO J. 3:3135-3141.
37. Everett R. 1984. A detailed analysis of an HSV-1 early promoter: sequences involved in trans-activation by viral immediate-early gene products are not early-gene specific. Nucleic Acids Res. 12:3037-3056.
38. O'Hare P, Hayward GS. 1985. Evidence for a direct role for both the 175,000-and 110,000-molecular-weight immediate-early proteins of herpes simplex virus in the transactivation of delayed-early promoters. J. Virol. 53:751-760.
39. O'Hare P, Hayward GS. 1985. Three trans-acting regulatory proteins of herpes simplex virus modulate immediate-early gene expression in a pathway involving positive and negative feedback regulation. J. Virol. 56:723-733.
40. Everett R. 1987. A detailed mutational analysis of Vmw110, a trans-acting transcriptional activator encoded by herpes simplex virus type 1. EMBO J. 6:2069-2076.
41. Gelman IH, Silverstein S. 1985. Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene. Proc. Natl. Acad. Sci. U. S. A. 82:5265-5269.
42. Lopez P, Van Sant C, Roizman B. 2001. Requirements for the nuclearcytoplasmic translocation of infected-cell protein 0 of herpes simplex virus 1. J. Virol. 75:3832-3840.
43. McLean T, Bachenheimer S. 1999. Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication. J. Virol.73:8415-8426.
44. Zachos G, Clements B, Conner J. 1999. Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1. J. Biol. Chem. 274:5097-5103.
45. Karaca G, Hargett D, McLean TI, Aguilar J, Ghazal P, Wagner EK, Bachenheimer SL. 2004. Inhibition of the stress-activated kinase, p38, does not affect the virus transcriptional program of herpes simplex virus type 1. Virology 329:142-156.
46. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
47. Shamu CE, Flierman D, Ploegh HL, Rapoport TA, Chau V. 2001. Polyubiquitination is required for US11-dependent movement of MHC class I heavy chain from endoplasmic reticulum into cytosol. Mol. Biol. Cell 12:2546-2555.
48. Schubert U, Antón LC, Bacčík I, Cox JH, Bour S, Bennink JR, Orlowski M, Strebel K, Yewdell JW. 1998. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 72:2280-2288.
49. Luo H, Zhang J, Dastvan F, Yanagawa B, Reidy MA, Zhang HM, Yang D, Wilson JE, McManus BM. 2003. Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J.Virol. 77:1-9.
50. Luo H, Zhang J, Cheung C, Suarez A, McManus BM, Yang D. 2003.Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am. J. Pathol. 163:381-385.
51. Everett RD, Freemont P, Saitoh H, Dasso M, Orr A, Kathoria M,Parkinson J. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72:6581-6591.
52. Pokrovskaja K, Mattsson K, Kashuba E, Klein G, Szekely L. 2001.Proteasome inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5. J. Gen. Virol. 82:345-358.
53. Satheshkumar P, Anton LC, Sanz P, Moss B. 2009. Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J. Virol. 83:2469-2479.
54. Greene W, Zhang W, He M, Witt C, Ye F, Gao SJ. 2012. The ubiquitin/proteasome system mediates entry and endosomal trafficking of Kaposi's sarcoma-associated herpesvirus in endothelial cells. PLoS Pathog.8:e1002703. doi:10.1371/journal.ppat.1002703.
55. Karpe YA, Meng XJ. 2012. Hepatitis E virus replication requires an active ubiquitin-proteasome system. J. Virol. 86:5948-5952.
56. Teale A, Campbell S, Van Buuren N, Magee WC, Watmough K,Couturier B, Shipclark R, Barry M. 2009. Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication. J. Virol.83:2099-2108.
57. Patel A, Hanson J, McLean TI, Olgiate J, Hilton M, Miller WE, Bachenheimer SL. 1998. Herpes simplex virus type 1 induction of persistent NFΚB nuclear translocation increases the efficiency of virus replication.Virology 247:212-222.
58. Gregory D, Hargett D, Holmes D, Money E, Bachenheimer S. 2004.Efficient replication by herpes simplex virus type 1 involves activation of the IΚB kinase-IΚB-p65 pathway. J. Virol. 78:13582-13590.
59. Regad T, Chelbi-Alix MK. 2001. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20:7274-7286.
60. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
61. Saffert RT, Kalejta RF. 2008. Promyelocytic leukemia-nuclear body proteins:herpesvirus enemies, accomplices, or both? Future Virol. 3:265-277.
62. Kapuria V, Peterson LF, Showalter H, Kirchhoff PD, Talpaz M, Donato NJ. 2011. Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. Biochem.Pharmacol. 82:341-349.
63. +-induced dopaminergic neuronal cell death: its potential role as a survival determinant.Biochem. Biophy. Res. Comm. 322:727-733.
64. Bureau C, Bernad J, Chaouche N, Orfila C, Béraud M, Gonindard C,Alric L, Vinel JP, Pipy B. 2001. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J. Biol. Chem. 276:23077-23083.
65. Israel N, Gougerot-Pocidalo MA. 1997. Oxidative stress in human immunodeficiency virus infection. Cell. Mol. Life Sci. 53:864-870.
66. Pace GW, Leaf CD. 1995. The role of oxidative stress in HIV disease. Free Radic. Biol. Med. 19:523-528.
67. Schachtele SJ, Hu S, Little MR, Lokensgard JR. 2010. Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2. J. Neuroinflamm. 7:35. doi:10.1186/1742-2094-7-35.
68. Gonzalez-Dosal R, Horan KA, Rahbek SH, Ichijo H, Chen ZJ, Mieyal JJ, Hartmann R, Paludan SR. 2011. HSV infection induces production of ROS, which potentiate signaling from pattern recognition receptors: role for S-glutathionylation of TRAF3 and 6. PLoS Pathog. 7:e1002250. doi:10.1371/journal.ppat.1002250.
69. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. 2002. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J. Infect. Dis. 186:1718-1725.
70. Everett RD. 2000. ICP 0, a regulator of herpes simplex virus during lytic and latent infection. Bioessays 22:761-770.
71. Everett RD, Boutell C, Orr A. 2004. Phenotype of a herpes simplex virus type 1 mutant that fails to express immediate-early regulatory protein ICP0. J. Virol. 78:1763-1774.
72. Thomas M, Pim D, Banks L. 1999. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18:7690-7700.
73. Klinger PP, Schubert U. 2005. The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Rev.Anti Infect. Ther. 3:61-79.
74. Widjaja I, de Vries E, Tscherne DM, Garciáa-Sastre A, Rottier PJM, de Haan CAM. 2010. Inhibition of the ubiquitin-proteasome system affects influenza A virus infection at a postfusion step. J. Virol. 84:9625-9631.
75. Si X, Gao G, Wong J, Wang Y, Zhang J, Luo H. 2008. Ubiquitination is required for effective replication of coxsackievirus B3. PLoS One 3:e2585. doi:10.1371/journal.pone.0002585.
76. Raaben M, Posthuma CC, Verheije MH, te Lintelo EG, Kikkert M, Drijfhout JW, Snijder EJ, Rottier PJM, de Haan CAM. 2010. The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. J. Virol. 84:7869-7879.
77. Kanlaya R, Pattanakitsakul S, Sinchaikul S, Chen ST, Thongboonkerd V. 2010. The ubiquitin-proteasome pathway is important for dengue virus infection in primary human endothelial cells. J. Proteome Res. 9:4960-4971.
78. Neznanov N, Dragunsky EM, Chumakov KM, Neznanova L, Wek RC, Gudkov AV, Banerjee AK. 2008. Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS One 3:e1887. doi:10.1371/journal.pone.0001887.
79. Everett RD, Orr A, Preston CM. 1998. A viral activator of gene expression functions via the ubiquitin-proteasome pathway. EMBO J. 17:7161-7169.
80. La Frazia S, Amici C, Santoro MG. 2006. Antiviral activity of proteasome in hibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB. Antiviral Ther. 11:995-1004.